After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer

  • Merck & Co Inc MRK announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating Keytruda (pembrolizumab) plus Eisai Co Ltd's ESALY Lenvima (lenvatinib) for the first-line treatment of advanced renal cell carcinoma (RCC)
  • These data will be presented at the upcoming American Society of Clinical Oncology Annual Meeting.
  • Also Read: Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer.
  • After four years of follow-up, Keytruda plus Lenvima maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21%. 
  • The 24- and 36-month estimated OS rates were 80.4% and 66.4% for Keytruda plus Lenvima versus 69.6% and 60.2% for Pfizer Inc's PFE Sutent (sunitinib), respectively. 
  • Keytruda plus Lenvima reduced the risk of disease progression or death by 53%, with a median progression-free survival (PFS) of 23.9 months versus 9.2 months for sunitinib.
  • The objective response rate (ORR) was 71.3%, with a complete response (CR) rate of 18.3% for Keytruda plus Lenvima versus an ORR of 36.7% with a CR rate of 4.8% for sunitinib.
  • There were no new safety signals, and the safety profile at the final OS analysis was consistent with the primary analysis. 
  • Price Action: MRK shares closed at $112.30 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!